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Abstract
Carbapenemases should be accurately and rapidly detected, given their possible epidemiological spread and their impact on treatment
options. Here, we developed a simple, easy and rapid matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)-based
assay to detect carbapenemases and compared this innovative test with four other diagnostic approaches on 47 clinical isolates.
Tandem mass spectrometry (MS-MS) was also used to determine accurately the amount of antibiotic present in the supernatant after
1 h of incubation and both MALDI-TOF and MS-MS approaches exhibited a 100% sensitivity and a 100% specificity. By comparison,
molecular genetic techniques (Check-MDR Carba PCR and Check-MDR CT103 microarray) showed a 90.5% sensitivity and a 100%
specificity, as two strains of Aeromonas were not detected because their chromosomal carbapenemase is not targeted by probes used
in both kits. Altogether, this innovative MALDI-TOF-based approach that uses a stable 10-lg disk of ertapenem was highly efficient in
detecting carbapenemase, with a sensitivity higher than that of PCR and microarray.
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Introduction
Antibiotic multiresistance is a major problem for treatment of
Gram-negative bacterial infections, especially those due to
Enterobacteriaceae and non-fermentative bacteria such as
Pseudomonas aeruginosa and Acinetobacter baumanii. The use of
carbapenems was a good alternative to cephalosporins, but
worldwide spread of carbapenem resistance may impair this
therapeutic alternative [1]. Carbapenem resistance may be
caused by a loss of porin or overexpression of active efflux [2],
but can also be due to the bacterial production of carbapen-
emases. Identification of carbapenemase-producing strains is
difficult and time-consuming in the diagnostic laboratory,
because the gene encoding this enzyme could be carried on a
plasmid often associated with other resistance genes. Misiden-
tification of carbapenemase resistance could lead to inappro-
priate antibiotic treatment and development of multiresistance
[3,4].
To investigate the Gram-negative bacterial isolates regard-
ing expression of carbapenemase, we used a panel of
approaches including various antibiotic susceptibility methods
such as E-test, disk diffusion assay and MIC in broth, as well
as a modified Hodge test and combined disk assays [5]. The
specificity and the sensitivity of these carbapenemase
identification tests are not precisely defined regarding the
different carbapenem enzymes and the modified Hodge test
may be difficult to interpret [6,7]. New promising biochem-
ical methods for detection of carbapenemase have been
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
described, and their place in the screening of carbapene-
mases has to be better defined [8–10].
Recently, matrix-assisted laser desorption ionization-time of
flight mass spectrometry (MALDI-TOF MS) was successfully
used to detect the activity of carbapenemase in an isolated
bacterial strain (i.e. its ability to degrade the antibiotic during a
2.5-h incubation with a carbapenem). Burckhardt et al. [11]
followed in vitro the degradation of carbapenems into hydro-
lyzed and decarboxylated products measured in incubation
supernatants with MALDI-TOF MS. The authors described the
complete disappearance within 2.5 h of signal peaks of ertape-
nem at an m/z value of 476, 498 and 521 Da. Similarly, Hrabak
et al. [12] also used MALDI-TOF MS to directly detect
meropenem and its degradation products in supernatants of
carbapenemase-positive or negative isolates. The presence or
the absence of specific meropenem peaks allowed the identi-
fication of the enzymatic carbapenem resistance phenotype. A
shorter and simpler MALDI-TOF-based technique is warranted.
Therefore, we developed a simplified technique compared
with that of Burckhardt et al., with a shorter incubation of the
strains investigated and with the use of a 10-lg commercialized
ertapenem impregnated disk, routinely used in clinical labora-
tories.
The ability of this new MALDI-TOF approach to detect
carbapenem resistance was assessed by investigating strains (i)
using phenotypic methods such as Vitek, e-tests and Hodge
test, (ii) using a modified liquid chromatography coupled to
tandem mass spectrometry (LC-MS/MS) assay (L.A. Deco-
sterd, B. Ternon, S. Cruchon, N. Guignard, S. Lahrichi, B.
Pesse, B. Rochat, T. Calandra, C. Csajka, T. Buclin, A. Mello, N.
Widmer and O. Marchetti, unpublished data), [13] that allows
the precise and accurate quantification of ertapenem concen-
trations in the incubation supernatant and (iii) using two rapid
molecular genetics techniques, which both detect the presence
of clinically relevant carbapenemase-encoding genes within a
single reaction: (a) the Check-MDR Carba detects the
plasmidic carbapenemases (i.e. KPC, OXA-48 and other
metallo-beta-lactamases (MBL) such as VIM and IMP, as well
as the rapidly emerging NDM-1); and (b) the Check-MDR
CT103 microarray, which identifies KPC, NDM-1, OXA-48,
VIM and IMP carbapenemase genes as well as TEM-, SHV- and
CTX-M-type ESBLs.
Materials and Methods
Antimicrobial susceptibility
Carbapenem MICs (ERT, IMP and MEM) were determined
with Etest (BioMerieux, Lyon, France) and interpreted
according to EUCAST guidelines. (European Committee on
Antimicrobial Susceptibility Testing. 2012. Breakpoint tables
for interpretation of MICs and zone diameters, version 2.0.
EUCAST, V€axj€o, Sweden. http://www.eucast.org/antimicro-
bial_susceptibility_testing). The two isolates used as refer-
ences were the carbapenemase-positive Klebsiella pneumoniae
(ATCC BAA-1705, bla KPC+) and the negative carbapenemase
strain Klebsiella pneumoniae (ATCC BAA-1706, (bla KPC).
Clinical isolates
We studied 47 non-repetitive clinical isolates presenting
resistance to cephalosporins and/or carbapenems, isolated
from January 2011 to December 2012 at our university
hospital centre. The following 37 Enterobacteriaceae isolates
were tested: Klebsiella pneumoniae (n = 10), Escherichia coli
(n = 9), Enterobacter cloacae (n = 7), Providencia stuartii (n = 2),
Serratia marcescens (n = 2), Enterobacter aerogenes (n = 3),
Hafnia alvei (n = 1), Klebsiella oxytoca (n = 1), Proteus vulgaris
(n = 1) and Morganella morganii (n = 1). We also tested 10
non-fermentative bacteria: Pseudomonas aeruginosa (n = 4),
Acinetobacter baumanii (n = 4) and Aeromonas (n = 2).
Carbapenemase assays
Phenotypic detection of carbapenemase production was
performed using the modified Hodge test recommended by
the Clinical and Laboratory Standards Institute (CLSI) and
Center for Disease Control (CDC) (CLSI. 19th Informational
Supplement. CLSI document M100-S19, 2009 and CDC: http://
www.cdc.gov/hai/). A suspension of Escherichia coli ATCC
25922, adjusted to 0.5 McFarland was inoculated on a Mueller-
Hinton agar plate. Then, an ertapenem disk (10 lg, BBL) was
placed at the centre of the agar plate. Control and test isolates
were streaked from the edge of the disk to the periphery of
the plate. The presence of a distorted inhibition zone after 16–
18 h of incubation at 37°C was interpreted as a positive
modified Hodge test. The imipenem/imipenem-inhibitor (IP/
IPI) E-test was used to screen for the presence of metallo-
beta-lactamase production. Interpretation of the results was
carried out according to the manufacturer’s instructions. After
16–18 h of incubation at 35°C, a reduction in MIC in the
presence of EDTA of greater than or equal to eight-fold was
interpreted as positive MBL activity.
Ertapenem degradation assay
The tested isolates were grown overnight on a blood agar
plate at 37°C. An inoculum of 7 on the McFarland scale was
resuspended in 1 mL of NaCl 0.45% in glass tubes. This
bacterial suspension was then incubated for 60 min at 37°C
with an ertapenem disk (10 lg) to reach a final concentration
of 10 mg/L. After incubation, 500 lL were centrifuged at
12 000 9 g for 2 min and 1 lL of the supernatant was used
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for MALDI-TOF MS analysis. Then, we added 1 lL of MALDI
matrix (a saturated solution of a-cyano-4-hydroxycinnamic
acid in 5% acetonitrile – 2.5% trifluoroacetic acid).
MALDI-TOF and spectrum data analysis
The analysis was carried out with the Bruker Daltonics
Microflex (Bremen, Germany). The detection parameter used
for the analysis was the Antibiotics_500.par provided by Bruker,
and the Mass Range was the ‘low level (300–800 Da)’ option.
Flex analysis 3.0 software was used to analyse the mass
spectrum, with windows ranging from 400 to 600 Da. Around
500 shots per spectrum were summed up, then all spectrums
were smoothed and the baseline was subtracted. All spectra of
the different incubation supernatants were analysed and com-
pared with the ertapenem incubation control diluted at 10 mg/L
and the supernatant of culture without ertapenem (blank).
MS-MS analysis
The ertapenem concentrations in enzymatic incubation
medium have been measured with a specific and sensitive
liquid chromatography-tandem mass spectrometry method
(LC-MS/MS) using an adaptation of validated multiplex assays
developed in our laboratory for the drug monitoring of
antimicrobials (L.A. Decosterd, B. Ternon, S. Cruchon, N.
Guignard, S. Lahrichi, B. Pesse, B. Rochat, T. Calandra, C.
Csajka, T. Buclin, A. Mello, N. Widmer and O. Marchetti,
unpublished data), [13]. Briefly, the enzymatic incubation
aliquot (100 lL) was added to 50 lL of Internal Standard
(I.S.) solution (cefazoline 18 mg/L) and was placed in ice at
+4°C. The resulting sample was carefully vortex-mixed with
methanol (300 lL). The mixture was then centrifuged at +4°C
for 10 min at 20 000 g (14 000 rpm) and an 80-lL aliquot of
the supernatant was diluted with 480 lL of ultrapure water
prior to HPLC-MS/MS analysis. Processed samples were
maintained at +4°C in the thermostat autosampler rack during
the entire LC-MS/MS analysis.
Reverse-phase chromatographic separation of ertapenem
(eluted at 2.6 min) was obtained using a gradient elution of the
mobile phase of 10 mM ammonium formic acid solution with
4% formic acid (FA) (solution A) and acetonitrile (solution B)
delivered onto the UPLC column Waters Acquity UPLC HSS
T3 2.1 9 50 mm (Waters, Milford, MA, USA), 1.8 lm, using
the following stepwise gradient elution program: 4% of B at
0 min to 90% of B at 5.5 min, followed by a re-equilibration
step to the initial solvent up to 9 min. Ertapenem quantification
using matrix-matched calibration samples (NaCl 150 mM) was
performed by electro-spray ionisation–triple quadrupole mass
spectrometry on a Quantum Ultra mass spectrometer
(Thermo Fisher Scientific Inc., Waltham, MA, USA), by selected
reaction monitoring detection using the transitions for ertape-
nem atm/z: 476.2? 432.7, 476.2? 114.4 and 476.2? 68.1, in
the positive mode. The lower limit of quantification of
ertapenem in incubation medium was 0.1 mg/L.
Molecular methods
Two molecular kits were used, which detect the presence of
most clinically relevant carbapenemase-encoding genes, the
Check-MDR Carba and the Check-MDR CT103 microarray.
These kits, designed by Check-Points Health BV (Wageningen,
the Netherlands), were used according to the manufacturer’s
instructions.
Results
Susceptibility to carbapenems
Thirteen of the 15 Enterobacteriaceae expressing carbapene-
mases were resistant to ertapenem with MIC >1 mg/L
(Table 1). Two Providencia stuartii carbapenemase isolates
exhibited no resistance to carbapenem (MIC ERT <0.064 mg/
L). In contrast, among seven carbapenemases expressed by
non-fermentative isolates, only three presented a high resis-
tance to ertapenem. The two Aeromonas isolates presented a
resistance to ertapenem even with concentrations lower than
1 mg/L.
Analysis of spectrum obtained with the two Klebsiella
pneumoniae reference isolates in the presence of ertapenem
The first reference isolate was a carbapenemase producer (KPC
strain) whereas the second one was resistant to carbapenem by
another resistance mechanism (AmpC-type enzyme combined
with porin loss). The analysis of the supernatant obtained with
both strains using MALDI-TOF MS revealed two different
molecular peaks (hereafter called peak A and peak B) that may
be used to detect a carbapenemase producer strain (Fig. 1). The
peak A appears at an m/z value of 476 Da in the absence of
carbapenemase, corresponding to the non-hydrolyzed form
(Ertapenem + H+), whereas it is displaced to 478 Da when
hydrolyzed. This 2 kDa increase probably reflects the presence
of an intermediate compound, the precise molecular compo-
sition of which remains to be determined. Similarly, peak B is
observed at an m/z value of 498 Da in the absence of a
carbapenemase, corresponding to the monosodium ertapenem
(Ertapenem + Na+), whereas it is displaced to 496 Da in the
presence of carbapenemase. However, for the KPC strain we
observed in our conditions, there was no complete disappear-
ance of 476, 498 and 521 Da peaks (corresponding to
ertapenem degradation products), probably due to a relatively
short incubation, which does not allow a complete ertapenem
hydrolysis.
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Analysis of the MALDI-TOF spectrum profiles of the clinical
isolates
The 37 Enterobacteriaceae and the 10 non-fermentative
bacteria presenting cephalosporins and/or carbapenems resis-
tance were tested for their MALDI-TOF profiles spectrum in
the presence of ertapenem. The analysis focusing on the two
peaks A and B described above allowed the identification of 22
isolates exhibiting the typical shifts of peaks A-476 and B-498,
compatible with carbapenemase degradation (Table 1). For the
Oxa48-positive Escherichia coli strain 7469, we observed a clear
shift of peak B, while peak A was only partially shifted to the
right. This modification possibly reflects the lower activity of
the Oxa-48-like enzyme (Fig. 1), a lower activity confirmed by
MS-MS (see below).
MS-MS analysis
In order to confirm the positive carbapenemase producers,
the degradation of ertapenem was assessed by LC-MS-MS in
all supernatants and compared with the MALDI-TOF results.
For all isolates identified as carbapenemase-positive by
MALDI-TOF, ertapenem concentration was around 0 mg/L,
except for three OXA-48-like producer isolates (Enterobacter
cloacae 8088, Serratia marcescens 5965 and Escherichia coli
7469), in which 1.9, 1.7 and 2.4 mg/L of ertapenem,
respectively, were detected in the culture media after
60 min of incubation with these isolates. Conversely, for all
non-carbapenemase producers, the concentration of ertape-
nem after 60 min of culture in the presence of the antibiotic
was always more than 6 mg/L and generally about 10 mg/L
(Fig. 2, Table 1).
Rapid molecular detection of clinically important
carbapenemase genes
The Check-MDR Carba was used to identify the most prevalent
carbapenemase-encoding genes [14]. Klebsiella pneumoniae
carbapenemase KPC, and metallo-beta-lactamase including
IMP, VIM and NDM 1, class D Oxa-48-like genes, could be
detected in a simple real-time PCR reaction. Of 47 isolates
tested, a total of 19 isolates presented a carbapenemase gene, all
belonging to the 22 strains identified to be carbapenemase
producers by using the MALDI-TOF and the MS-MS approach
(see below). Results were confirmed by theCheck-MDRCT103
microarray. Eleven of the 47 isolates were AmpC producers
(MIR-ACT group, CMY II, DHA and ACC), with three associ-
ated with a carbapenemase gene (Oxa-48, VIM and NDM).
Among 16 extended-spectrum beta-lactamase (ESBL) isolates
 
 
Negative carbapenemase 
(Enterobacter cloacae 6354) 
Peak Peak
Positive carbapenemase 
(Pseudomonas aeruginosa 7752) 
Positive carbapenemase 
(Oxa48-Escherichia coli 7469)
(b)
 
(a)
FIG. 1. Matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF)
spectra of supernatants after 1 h
incubation of a KPC Klebsiella pneumoniae
positive control (red line), a negative
K. pneumoniae control (blue line) and the
tested strain (green line), in the presence
of ertapenem. Ertapenem degradation is
shown when peak A (476 Da) and peak B
(498 Da) are shifted. Dotted blue lines
show the position of A and B peaks for
negative strains whereas the dotted red
line shows the position of A and B peaks
for carbapenemase-producing strains.
Please note that only the B peak
obtained with the Oxa48 Escherichia coli
7469 strain exhibited a clear shift.
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(CTX and SHV), eight co-expressed carbapenemase genes
(KPC, VIM and NDM). Finally, a total of five KPC, 12 MBL
producers (nine VIM and three NDM) and three Oxa-48-like
encoding genes were detected. For 10 beta-lactamine-resistant
isolates, no expression of beta-lactamase was observed with
molecular approaches (Check MDR 103 and microarray
(Table 1)). Moreover, no carbapenemase genes were detected
by PCR and microarray in four isolates presenting a modified
Hodge test and/or an IP/IPI positive test. In addition, two
Aeromonas strains with a natural resistance to carbapenems
encoded on the bacterial chromosome were not detected using
the Check-MDR Carba, as expected [15].
Test performance
Using a reference standard based on the results from five
different approaches, true-positive carbapenemase producers
were defined as 3/5 (n = 2), 4/5 (n = 2) or 5/5 (n = 17) positive
tests and true-negatives were defined as 0/5 (n = 24) or 1/5
(n = 3) negative tests. Thus, in this work, a total of 21 positive
and 28 negative isolates were included (Table 1). The sensitiv-
ities of the different diagnostic approaches ranged from 90% to
100%, whereas the specificities ranged from 86% to 100%
(Table 2). The two spectrometry approaches (MALDI-TOF and
MS-MS) exhibited the best sensitivities and specificities (100%).
Although a specificity of 100%was obtainedwith bothmolecular
approaches (MDR Carba and Check MDR 103), the specificities
of these techniques exhibited only 90% (19/21). The modified
Hodge test using ertapenem successfully identified 19/21 (90%)
of the carbapenemase producers. False-negative modified
Hodge test results were obtained for two isolates producing
metallo-beta-lactamases (i.e. NDM and VIM, respectively).
False-positive results were obtained for three Enterobacter
spp., including one AmpC hyperproducer.
Discussion
It is now well established that the MALDI-TOF can be used not
only for bacterial identification [16,17] but also can be applied
in other important areas of diagnostic bacteriology, such as the
detection of antibiotic modifications mediated by enzymatic
expression of different enzymes (beta-lactamase and carbape-
nemase) [11,18].
In this study, we developed an easy, robust and rapid
technique for identification of carbapenemase in Gram-nega-
tive isolates by MALDI-TOF mass spectroscopy in 1 h. The
degradation of the ertapenem antibiotic was analysed by
MALDI-TOF mass spectrometry by comparing the pattern of
peak profiles obtained between 300 and 800 Da (m/z).
Ertapenem was used in our experiment because it appears
to be the most promising Carbapenemase for detection of
KPC and carbapenem producers. Our new approach is highly
efficient for detecting carbapenemase activity, exhibiting a
100% congruency with quadrupole mass spectrometry and
overall exhibiting 100% sensitivity and 100% specificity on the
47 strains investigated here. Check-point PCR and check-point
microarray have been shown to be sensitive and specific
techniques. However, the longer time to results and higher
cost make them relatively useless. In our MALDI-TOF assay,
the use of disk diffusion has the advantage of having a stable
and calibrated carbapenem concentration to ease testing in the
setting of a routine diagnostic laboratory.
In conclusion, we modified a previously described MAL-
DI-TOF technique to detect the presence of carbapenemases,
using a simple 1-h MALDI-TOF-based test. Our innovative
approach, which uses a 10-lg disk of ertapenem (available in any
laboratory using this disk diffusion test) was highly efficient in
detecting carbapenemases, with a sensitivity higher than that of
FIG. 2. Ertapenem concentration as measured by MS/MS according to
the presence of carbapenemase as determined by matrix-assisted laser
desorption ionization-time of flight mass spectrometry (MALDI-TOF
MS). Please note that the positive control obtainedwith the 10-mg disk in
the absence of any bacterial strain is shown in the right column.
TABLE 2. Sensitivity, specificity of different diagnostic
approaches, phenotypic, PCR, microarray, matrix-assisted
laser desorption ionization-time of flight (MALDI-TOF) and
MS/MS
Diagnostic approach Sensitivity Specificity
Phenotypic detection
(modified Hodge test)
90.5% (19/21) 86% (24/28)
Phenotypic detection (IP/IPI)a 54.5% (6/11) 92.1% (35/38)
PCR-Check MDR Carba 90.5% (19/21) 100% (28/28)
Microarray 90.5% (19/21) 100% (28/28)
MALDI-TOF 100% (21/21) 100% (28/28)
MS/MS 100% (21/21) 100% (28/28)
aPhenotypic detection of metallo-beta-lactamases (VIM, IMP and NDM).
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PCR and microarray. MS-MS measurement of ertapenem after
incubation of the 10-lg disk with the investigated strain is an
alternative that showed 100% congruency with MALDI-TOF.
Despite allowing more precise quantification, it has the limita-
tion, unlike MALDI-TOF, of not always being available in clinical
bacteriology laboratories, and necessitates a costly MS-MS
infrastructure and the specific know-how of expert chemistry
technicians.
Conversely, the MALDI-TOF-based approach that we
report here has the advantage of being cheap, highly accurate
and rapid (overall TAT about 1 h 15 min) and can be
performed in any laboratory equipped with a MALDI-TOF,
which is now part of the routine equipment of any diagnostic
laboratory. However, the spectra should be manually inter-
preted by a specifically trained technician, at least until an
automated interpretation algorithm is developed and imple-
mented in the Bruker software.
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